Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2016 Jan 26;315(4):362-70.
doi: 10.1001/jama.2015.18589.
Vincent J Carey 1, Nancy Laranjo 2, Benjamin J Harshfield 2, Thomas F McElrath 3, George T O'Connor 4, Megan Sandel 5, Ronald E Iverson Jr 6, Aviva Lee-Paritz 6, Robert C Strunk 7, Leonard B Bacharier 7, George A Macones 8, Robert S Zeiger 9, Michael Schatz 9, Bruce W Hollis 10, Eve Hornsby 11, Catherine Hawrylowicz 11, Ann Chen Wu 12, Scott T Weiss 1
Affiliations
- PMID: 26813209
- PMCID: PMC7479967
- DOI: 10.1001/jama.2015.18589
Randomized Controlled Trial
Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial
Augusto A Litonjua et al. JAMA. 2016.
Abstract
Importance: Asthma and wheezing begin early in life, and prenatal vitamin D deficiency has been variably associated with these disorders in offspring.
Objective: To determine whether prenatal vitamin D (cholecalciferol) supplementation can prevent asthma or recurrent wheeze in early childhood.
Design, setting, and participants: The Vitamin D Antenatal Asthma Reduction Trial was a randomized, double-blind, placebo-controlled trial conducted in 3 centers across the United States. Enrollment began in October 2009 and completed follow-up in January 2015. Eight hundred eighty-one pregnant women between the ages of 18 and 39 years at high risk of having children with asthma were randomized at 10 to 18 weeks' gestation. Five participants were deemed ineligible shortly after randomization and were discontinued.
Interventions: Four hundred forty women were randomized to receive daily 4000 IU vitamin D plus a prenatal vitamin containing 400 IU vitamin D, and 436 women were randomized to receive a placebo plus a prenatal vitamin containing 400 IU vitamin D.
Main outcomes and measures: Coprimary outcomes of (1) parental report of physician-diagnosed asthma or recurrent wheezing through 3 years of age and (2) third trimester maternal 25-hydroxyvitamin D levels.
Results: Eight hundred ten infants were born in the study, and 806 were included in the analyses for the 3-year outcomes. Two hundred eighteen children developed asthma or recurrent wheeze: 98 of 405 (24.3%; 95% CI, 18.7%-28.5%) in the 4400-IU group vs 120 of 401 (30.4%, 95% CI, 25.7%-73.1%) in the 400-IU group (hazard ratio, 0.8; 95% CI, 0.6-1.0; P = .051). Of the women in the 4400-IU group whose blood levels were checked, 289 (74.9%) had 25-hydroxyvitamin D levels of 30 ng/mL or higher by the third trimester of pregnancy compared with 133 of 391 (34.0%) in the 400-IU group (difference, 40.9%; 95% CI, 34.2%-47.5%, P < .001).
Conclusions and relevance: In pregnant women at risk of having a child with asthma, supplementation with 4400 IU/d of vitamin D compared with 400 IU/d significantly increased vitamin D levels in the women. The incidence of asthma and recurrent wheezing in their children at age 3 years was lower by 6.1%, but this did not meet statistical significance; however, the study may have been underpowered. Longer follow-up of the children is ongoing to determine whether the difference is clinically important.
Trial registration: clinicaltrials.gov Identifier: NCT00920621.
Conflict of interest statement
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Litonjua reported receiving personal fees from UpToDate Inc and Springer Humana Press. Dr McElrath reported receiving grants from the National Institutes of Health (NIH). Dr O’Connor reported receiving grants from the NIH. Dr Bacharier reported receiving grants from the NIH and National Heart, Lung, and Blood Institute (NHBLI), and personal fees from Aerocrine, GlaxoSmithKline, Genentech/Novartis, Merck, Schering, Cephalon, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi, and Vectura. Dr Zeiger reported receiving grants from the NHBLI, AstraZeneca, Aerocrine, MedImmune, Genentech, Merck, and GlaxoSmithKline and personal fees from Genentech, Novartis, GlaxoSmithKline, and TEVA. Dr Hornsby reported receiving an NIH ancillary grant. Dr Hawrylowicz reported receiving an NIH ancillary grant, a fellowhip grant from Wellcome Trust Clinical Training Research Fellowship, grant G100758 from the Medical Research Council Centre, and grants from Asthma UK, the Lord Leonard and Lady Estelle Wolfson Foundation, and the Alpha 1 Foundation. No other disclosures were reported.
Figures
Figure 1.. The VDAART Participant Flow
IVF indicates in vitro fertilization.
Figure 2.. Asthma or Recurrent Wheeze-Free Proportion by Treatment
Kaplan-Meier survival estimates. Error bars indicate 95% CI estimates at intervals of 1, 2, and 3 years. Estimates were obtained from nonparametric maximum likelihood estimation, with optimal nonparametric testing with interval-censored response times. These interval-censored response times lead to gaps in the curves, which we have denoted with diagonal lines. The hazard ratio for the time to first event of asthma or recurrent wheeze was 0.8 (95% CI, 0.6–1.0; P value = .051).
Comment in
- Inconclusive Results of Randomized Trials of Prenatal Vitamin D for Asthma Prevention in Offspring: Curbing the Enthusiasm.
von Mutius E, Martinez FD. von Mutius E, et al. JAMA. 2016 Jan 26;315(4):347-8. doi: 10.1001/jama.2015.18963. JAMA. 2016. PMID: 26813205 No abstract available. - Prenatal Vitamin D and Offspring Wheezing.
Bhaskaran K, Smeeth L, Evans S. Bhaskaran K, et al. JAMA. 2016 Jun 28;315(24):2730. doi: 10.1001/jama.2016.4108. JAMA. 2016. PMID: 27367769 No abstract available. - Prenatal Vitamin D and Offspring Wheezing.
Merenstein D, D'Amico F. Merenstein D, et al. JAMA. 2016 Jun 28;315(24):2731. doi: 10.1001/jama.2016.4111. JAMA. 2016. PMID: 27367771 No abstract available. - Prenatal Vitamin D and Offspring Wheezing--Reply.
Litonjua AA, Weiss ST. Litonjua AA, et al. JAMA. 2016 Jun 28;315(24):2731. doi: 10.1001/jama.2016.4121. JAMA. 2016. PMID: 27367772 No abstract available.
Similar articles
- The Impact of Baseline 25-Hydroxyvitamin D Level and Gestational Age on Prenatal Vitamin D Supplementation to Prevent Offspring Asthma or Recurrent Wheezing.
Shadid IL, Brustad N, Lu M, Chawes BL, Bisgaard H, Zeiger RS, O'Connor GT, Bacharier LB, Guchelaar HJ, Litonjua AA, Weiss ST, Mirzakhani H. Shadid IL, et al. Am J Clin Nutr. 2023 Jun;117(6):1342-1352. doi: 10.1016/j.ajcnut.2023.04.019. Epub 2023 Apr 17. Am J Clin Nutr. 2023. PMID: 37075847 Free PMC article. Clinical Trial. - Effect of Vitamin D3 Supplementation During Pregnancy on Risk of Persistent Wheeze in the Offspring: A Randomized Clinical Trial.
Chawes BL, Bønnelykke K, Stokholm J, Vissing NH, Bjarnadóttir E, Schoos AM, Wolsk HM, Pedersen TM, Vinding RK, Thorsteinsdóttir S, Arianto L, Hallas HW, Heickendorff L, Brix S, Rasmussen MA, Bisgaard H. Chawes BL, et al. JAMA. 2016 Jan 26;315(4):353-61. doi: 10.1001/jama.2015.18318. JAMA. 2016. PMID: 26813208 Clinical Trial. - Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction.
Litonjua AA, Carey VJ, Laranjo N, Stubbs BJ, Mirzakhani H, O'Connor GT, Sandel M, Beigelman A, Bacharier LB, Zeiger RS, Schatz M, Hollis BW, Weiss ST. Litonjua AA, et al. N Engl J Med. 2020 Feb 6;382(6):525-533. doi: 10.1056/NEJMoa1906137. N Engl J Med. 2020. PMID: 32023372 Free PMC article. Clinical Trial. - Prenatal vitamin D supplementation to prevent childhood asthma: 15-year results from the Vitamin D Antenatal Asthma Reduction Trial (VDAART).
Weiss ST, Mirzakhani H, Carey VJ, O'Connor GT, Zeiger RS, Bacharier LB, Stokes J, Litonjua AA. Weiss ST, et al. J Allergy Clin Immunol. 2024 Feb;153(2):378-388. doi: 10.1016/j.jaci.2023.10.003. Epub 2023 Oct 16. J Allergy Clin Immunol. 2024. PMID: 37852328 Review. - Vitamin D supplementation for women during pregnancy.
De-Regil LM, Palacios C, Lombardo LK, Peña-Rosas JP. De-Regil LM, et al. Cochrane Database Syst Rev. 2016 Jan 14;(1):CD008873. doi: 10.1002/14651858.CD008873.pub3. Cochrane Database Syst Rev. 2016. PMID: 26765344 Updated. Review.
Cited by
- Vitamin D beyond the blood: Tissue distribution of vitamin D metabolites after supplementation.
Shadid ILC, Guchelaar HJ, Weiss ST, Mirzakhani H. Shadid ILC, et al. Life Sci. 2024 Oct 15;355:122942. doi: 10.1016/j.lfs.2024.122942. Epub 2024 Aug 10. Life Sci. 2024. PMID: 39134205 Review. - Vitamin D supplementation for women during pregnancy.
Palacios C, Kostiuk LL, Cuthbert A, Weeks J. Palacios C, et al. Cochrane Database Syst Rev. 2024 Jul 30;7(7):CD008873. doi: 10.1002/14651858.CD008873.pub5. Cochrane Database Syst Rev. 2024. PMID: 39077939 Review. - Vitamin D constrains inflammation by modulating the expression of key genes on Chr17q12-21.1.
Kilic A, Halu A, De Marzio M, Maiorino E, Duvall MG, Bruggemann TR, Rojas Quintero JJ, Chase R, Mirzakhani H, Sungur AÖ, Koepke J, Nakano T, Peh HY, Krishnamoorthy N, Abdulnour RE, Georgopoulos K, Litonjua AA, Demay M, Renz H, Levy BD, Weiss ST. Kilic A, et al. Elife. 2024 Apr 3;12:RP89270. doi: 10.7554/eLife.89270. Elife. 2024. PMID: 38567749 Free PMC article. - Investigating the role of vitamin D in asthma.
Sharma S, Garg M. Sharma S, et al. Elife. 2024 Apr 3;13:e97031. doi: 10.7554/eLife.97031. Elife. 2024. PMID: 38567741 Free PMC article. - Environmental Interventions for Preventing Atopic Diseases.
Pfirrman S, Devonshire A, Winslow A. Pfirrman S, et al. Curr Allergy Asthma Rep. 2024 May;24(5):233-251. doi: 10.1007/s11882-024-01141-1. Epub 2024 Mar 16. Curr Allergy Asthma Rep. 2024. PMID: 38492159 Review.
References
- Strachan D, Gerritsen J. Long-term outcome of early childhood wheezing: population data. Eur Respir J Suppl. 1996;21:42s–47s. - PubMed
- Zosky GR, Berry LJ, Elliot JG, James AL, Gorman S, Hart PH. Vitamin D deficiency causes deficits in lung function and alters lung structure. Am J Respir Crit Care Med. 2011;183(10):1336–1343. - PubMed
- Ferreira GB, Gysemans CA, Demengeot J, et al. 1,25-Dihydroxyvitamin D3 promotes tolerogenic dendritic cells with functional migratory properties in NOD mice. J Immunol. 2014;192(9):4210–4220. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 HL091528/HL/NHLBI NIH HHS/United States
- U54 TR001012/TR/NCATS NIH HHS/United States
- G100758/WT_/Wellcome Trust/United Kingdom
- U01HL091528/HL/NHLBI NIH HHS/United States
- G1000758/MRC_/Medical Research Council/United Kingdom
- WT_/Wellcome Trust/United Kingdom
- U54TR001012/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical